The Phia Group Blog

By: David Ostrowsky The Center for Drug Evaluation and Research (CDER), charged with regulating most prescription drugs and over-the-counter medicines, is quite possibly the most high-powered regulatory division of the U.S. Food and Drug Administration (FDA). Indeed, tens of millions…

By: David Ostrowsky For the better part of the 2020s, Pharmacy Benefit Managers, more colloquially known as PBMs, have been heavily scrutinized and even maligned for their business practices. Some critics have alleged that PBMs are responsible for engaging in…

By: Naga Vivekanandan, Esq. Those in the healthcare space, or generally anyone who uses social media, has likely heard a lot of buzz about GLP-1 medications lately. Originally developed for diabetes treatment, drugs like Ozempic, Wegovy, and Mounjaro have become…

By: David Ostrowsky When Maria Branyas Morera came into the world on March 4, 1907, Theodore Roosevelt was president, movie theater admission was a nickel, and electric washing machines had yet to become standard household items. In August 2024, Morera,…

By: Jon Jablon, Esq. Overpayment recovery can be messy even on a good day. As we all know all too well, without a contract, there’s no meaningful cap on what a provider can charge for its services; the provider’s legal…

By: Kendall Jackson, Esq. Each year, self-funded health plans must adhere to an array of disclosure, notice, and filing requirements, and compliance with these requirements already carries a degree of stress. While compliance with annual requirements would in theory be…